Medically Reviewed Content
Written by Rob Anderson, Health Technology Researcher & Medical Content Specialist. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting any medication.
Wegovy and Ozempic both contain semaglutide — but they are different products approved for different indications, at different doses, with different insurance coverage profiles and very different out-of-pocket costs. Here is the complete breakdown.
The Key Differences
| Ozempic | Wegovy | |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| FDA approval | Type 2 diabetes | Chronic weight management |
| Max dose | 2mg | 2.4mg |
| List price/month | ~$936 | ~$1,349 |
| Insurance (diabetes) | Usually covered | Less commonly |
| Insurance (weight) | Off-label — harder | Increasingly covered |
| Compounded alternative | $149–$299/month (same active ingredient) | |
Why Doctors Prescribe Ozempic for Weight Loss
Even though Wegovy is technically the approved weight management product, physicians frequently prescribe Ozempic off-label for weight loss — particularly for patients with insurance that covers diabetes medications but not weight management. The difference between Ozempic’s 2mg max and Wegovy’s 2.4mg max is clinically marginal for most patients.
The Compounded Semaglutide Option
Compounded semaglutide — produced by FDA-registered compounding pharmacies and prescribed through telehealth platforms — is the most accessible option for patients without insurance coverage. It contains the same active semaglutide molecule at the same doses, prepared under pharmacy regulations. Cost: typically $149–$299/month depending on dose and provider. The FDA permitted compounding during the Ozempic/Wegovy shortage period; as of 2026, the availability of compounded semaglutide is subject to ongoing FDA policy — check current status with your provider.
Insurance Navigation Tips
For Wegovy coverage: many commercial plans require prior authorisation with documentation of BMI and comorbidities. Novo Nordisk’s NovoCare programme provides savings cards reducing cost to $0–$99/month for eligible commercially-insured patients. For Medicare: Wegovy is covered under Part D since 2024 for patients with established cardiovascular disease (post-SELECT trial approval). Check your plan’s formulary at the start of each year as coverage changes frequently.
Frequently Asked Questions
Q: Is Wegovy cheaper than Ozempic?
A: Brand Wegovy and brand Ozempic have similar list prices ($936–$1,349/month) but insurance coverage differs significantly. Ozempic is more likely to be covered by insurance for type 2 diabetes. Wegovy has coverage under many commercial plans for weight management. For most patients without insurance coverage, compounded semaglutide ($149–$299/month) is dramatically cheaper than either brand product.
Q: What is the cheapest way to get semaglutide?
A: Compounded semaglutide from an FDA-registered pharmacy via a telehealth provider is consistently the cheapest route — typically $149–$299/month depending on dose and provider. This is 70–85% cheaper than brand Ozempic or Wegovy without insurance. Compounded semaglutide contains the same active ingredient (semaglutide base) at the same doses.
Q: Does insurance cover Wegovy in 2026?
A: Many commercial insurance plans now cover Wegovy for weight management following CMS updates and growing employer adoption of obesity treatment benefits. Coverage varies significantly by plan. Medicare covers Wegovy since 2024 under Part D for cardiovascular risk reduction (following the SELECT trial approval). Always verify your specific plan’s formulary and prior authorization requirements.
📖 Further Reading
Compare Compounded Semaglutide Providers
From $149/month with physician oversight. No insurance needed.
Sponsored | Affiliate link
Affiliate disclosure: This article contains affiliate links. See our Affiliate Disclosure.
Sources & References
- U.S. Food and Drug Administration (FDA) – Drug Approvals and Databases
- National Institutes of Health (NIH) – PubMed Medical Literature
- American Diabetes Association – Medication & Therapies
- Novo Nordisk – Clinical Research Data
- Eli Lilly – Medical Information
This content is regularly reviewed and updated to reflect the latest medical research and FDA guidance.